ClinicalTrials.gg
CompletedNCT02964273Updated Jan 3, 2023Results posted

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

A Phase 3 interventional study of Tolvaptan and Tolvaptan Matching-placebo in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 20 sites in 4 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-01-03.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
9th of 18
91 · median 91
Started
2016
with 1 other
Phase 3
8 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 8 in phase 3, and was the 14th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

The primary objective of the study is to assess the long term safety of treatment with tolvaptan in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). The secondary objective is to assess the pharmacodynamics, pharmacokinetics, and efficacy of tolvaptan in the same participant population.

Read the detailed description

Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (chronic kidney disease [CKD] stages 1 to 3) as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV).

This trial will be the first trial of tolvaptan in children and adolescents with ADPKD.

Participants in this study will be randomly assigned to one of two groups in Phase A; tolvaptan or placebo. Participants will have an equal chance of being assigned to either treatment group and will be stratified by age and gender into the following cohorts:

  • Female participant ages 12 to 14 years, inclusive
  • Female participant ages 15 to 17 years, inclusive
  • Male participant ages 12 to 14 years, inclusive
  • Male participant ages 15 to 17 years, inclusive

Phase (A) of this study will last 12 months. After that time, all participants who qualify will be assigned tolvaptan and will be treated with tolvaptan for 24 months (Phase B).

A qualified participant is defined as one who has completed Phase A on investigational medicinal product (IMP), is willing to continue in the trial, and who does not have any adverse events (AEs), which would require IMP discontinuation.

Participants in this study will be required to make monthly visits to the study clinic and will be closely monitored over the course of the study.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

  • Autosomal Dominant Polycystic Kidney Disease
  • ADPKD
  • Tolvaptan
  • Renal cysts
  • Chronic Kidney Disease
  • Genetic Kidney Disease
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male and female participants aged 4 to 17 years (inclusive) with a diagnosis of ADPKD as defined by the presence of family history and/or genetic criteria AND who have at least 10 renal cysts, each of which measure at least 0.5 cm, confirmed upon magnetic resonance imaging (MRI) inspection; participants under the age of 12 years must have at least 4 cysts that are at least 1 cm in size, confirmed by ultrasound.
  • Weight ≥20 kg.
  • Participants with estimated (eGFR) ≥ 60 mL/min/1.73m\^2 within 31 days prior to randomization (using the Schwartz formula, eGFR = 0.413 × height [cm]/serum creatinine milligrams per deciliter [mg/dL]).
  • Independent in toileting.
  • Ability to swallow a tablet.

Key Exclusion Criteria:

  • Liver function tests including (AST), alanine aminotransferase (ALT) > 1.5 × the (ULN).
  • Nocturnal enuresis.
  • Need for chronic diuretic use.
  • Participants with advanced diabetes (e.g., glycosylated >7.5, and/or glycosuria by dipstick, significant proteinuria, retinopathy), evidence of additional significant renal disease(s) (i.e., currently active glomerular nephritides), renal cancer, single kidney, or recent (within 6 months of screening) renal surgery or acute kidney injury.
  • Participants having disorders in thirst recognition or inability to access fluids.
  • Participants with critical electrolyte imbalances, as determined by the investigator.
  • Participants with, or at risk of, significant hypovolemia as determined by investigator.
  • Participants with anemia, as determined by investigator.
  • Participants 12 years of age and older having to, or interference with MRI assessments (e.g., ferro-magnetic prostheses, aneurysm clips, severe claustrophobia).
  • Participants with a history of taking a vasopressin agonist/antagonist.
  • Participants taking medications or having concomitant illnesses likely to confound endpoint assessments, including taking approved (i.e., marketed) therapies for the purpose of affecting polycystic kidney disease (PKD) cysts such as tolvaptan, vasopressin antagonists, anti-sense ribonucleic acid (RNA) therapies, rapamycin, sirolimus, everolimus, or somatostatin analogs (i.e., octreotide, sandostatin).
  • Participants who have had cyst reduction surgery within 6 weeks of the screening visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Phase A: Tolvaptan

    Participants received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting doses based on their weight as per the following specifications: ≥20 to 45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.

    Drug: Tolvaptan

  • Placebo comparator
    Phase A: Placebo

    Participants received matching-placebo tablets, orally as a split-dose (with the first dose taken upon awakening and second dose taken approximately 8 hours later), and starting dose based on their weight as per the following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.

    Drug: Tolvaptan Matching-placebo

  • Experimental
    Phase B: Prior Tolvaptan

    Qualified participants (defined as those who were willing to continue in the trial and who did not have any adverse events \[AEs\] that would require investigational medicinal product \[IMP\] discontinuation) who received tolvaptan and completed Phase A were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting dose based on their body weight as per following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.

    Drug: Tolvaptan

  • Experimental
    Phase B: Prior Placebo

    Qualified participants (defined as those who were willing to continue in the trial and who did not have any AEs that would require IMP discontinuation) who received matching-placebo and completed Phase A, were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), based on their current body weight as per following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.

    Drug: Tolvaptan

Interventions

  • Tolvaptan spray-dried, immediate release tablets

    Also known as: OPC-41061

  • DrugTolvaptan Matching-placebo

    Tolvaptan matching-placebo tablets

06

What researchers measure

Primary outcomes

  1. Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose)

    Urine osmolality is a measure of urine concentration, measured by osmometer, which evaluates the freezing point depression of a solution and supplies results as milliosmoles per kilogram of water. Spot urine osmolality was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.

    Time frame: Baseline, and Week 1 of Phase A

  2. Phase A: Change From Baseline in Specific Gravity (Pre-morning Dose)

    Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Spot urine sample for determination of specific gravity was collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.

    Time frame: Baseline, and Week 1 of Phase A

Secondary outcomes

  1. Phase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI)

    htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.

    Time frame: Baseline, and Month 12 of Phase A

  2. Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1

    Participants were instructed to record all fluid taken and all urine output for the 24-hour period.

    Time frame: Prior to Week 1 in Phase A and B

  3. Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A

    Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points. The units for the data reported are milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). The baseline was the evaluation done at Week 1 in Phase A for this outcome measure.

    Time frame: Phase A Baseline, Months 1, 6, and 12

  4. Phase B: Change From Phase B Baseline in Renal Function (eGFR by Schwartz Formula) at Each Clinic Visit in Phase B

    Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points.

    Time frame: Phase B Baseline, Week 1, Months 1, 6, 12, 18, and 24

  5. Phase B: Percent Change From Phase B Baseline in htTKV as Measured by MRI at Month 12 and Month 24

    htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.

    Time frame: Phase B Baseline, Months 12 and 24

  6. Phase A: 24-hour Urine Volume

    Urine volume refers to the quantity of urine produced per unit of time.

    Time frame: 24 hours post dose after Month 1 on study medication in Phase A

  7. Phase A: 24-hour Fluid Intake

    Daily fluid intake (total water) is defined as the amount of water consumed from foods, plain drinking water, and other beverages.

    Time frame: 24 hours post dose after Month 1 on study medication in Phase A

  8. Phase A: 24-hour Fluid Balance

    Fluid balance is a term used to describe the balance of the input and output of fluids in the body to allow metabolic processes to function correctly.

    Time frame: 24 hours post dose after Month 1 on study medication in Phase A

  9. Phase A: 24-hour Sodium Clearance

    Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.

    Time frame: 24 hours post dose after Month 1 on study medication in Phase A

  10. Phase A: 24-hour Creatinine Clearance

    Creatinine is produced from the metabolism of protein, when muscles burn energy. Most creatinine is filtered out of the blood by the kidneys and excreted in urine. The creatinine clearance value is determined by measuring the concentration of endogenous creatinine (that which is produced by the body) in both plasma and urine. Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.

    Time frame: 24 hours post dose after Month 1 on study medication in Phase A

  11. Phase A: 24-hour Free Water Clearance

    Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.

    Time frame: 24 hours post dose after Month 1 on study medication in Phase A

  12. Phase A: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations

    Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.

    Time frame: At Baseline, Months 6 and 12 of Phase A

  13. Phase B: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations

    Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.

    Time frame: At Baseline, Months 6, 12, 18, and 24 of Phase B

  14. Phase A: Change From Baseline in Growth Percentile by Gender and Age

    The growth percentile was based on the assessment of height and weight.

    Time frame: At Baseline, Months 6 and 12 of Phase A

  15. Phase B: Change From Baseline in Growth Percentile by Gender and Age

    The growth percentile was based on the assessment of height and weight.

    Time frame: At Baseline, Months 6, 12, 18, and 24 of Phase B

  16. Phase A: Change From Baseline in Creatinine Value

    Phase A Baseline is the last pre-dose evaluation. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan and Phase A: Placebo)

    Time frame: Baseline, Week 1, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, Follow Up Day 7, End of Treatment, and Last Visit

  17. Phase B: Change From Baseline in Creatinine Value

    Phase B Baseline is the last evaluation prior to the first dose in Phase B. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase B: Prior Tolvaptan and Phase B: Prior Placebo).

    Time frame: Baseline, Week 1, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, Follow Up Day 7, End of Treatment, and Last Visit

  18. Phase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Vital Signs

    Vital sign measurements included measurements of respiratory rate, blood pressure, body temperature and pulse. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. Only those categories with at least one participant with event are reported. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).

    Time frame: From first dose of study drug up to 14 days post last dose (up to approximately 37 months)

  19. Phase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Test Results Including Liver Function Tests (LFTs)

    Laboratory parameters=haematology,chemistry,urinalysis,\& LFTs.Criteria for laboratory abnormalities along with their test result grade=Increased creatinine level: Baseline(BSL):Grade 0,\>BSL-1.5xBSL:1,\>1.5-3xBSL:2,\>3-6xBSL:3,\>6xBSL:4.Decreased glucose level: \<30:-4,30-\<40:-3, 40-\<55:-2, 55-\<65:-1,\>=65:0; Increased:\<=115:0,\>115-160:1,\>160-250:2,\>250-500:3,\>500:4.Decreased potassium level: \<2.5:-4,2.5-\<3:-3,3-\<lower limit of normal(LLN):-1,LLN:0; Increased:upper limit of normal(ULN):0,\>ULN-5.5:1,\>5.5-6:2,\>6-7:3,\>7:4.Decreased sodium level: \<120:-4,120-124:-3,125-129:-2,130-135:-1,\>=136:0; Increased:\<=145:0,146-150:1,151-155:2,156-160:3,\>160:4. Increased triglyceride level:ULN:0,\>ULN-2.5xULN:1,\>2.5-5xULN:2,\>5-6xULN:3,\>6xULN:4. Decreased Neutrophils:\<0.5:-4,0.5-\<1:-3,1-\<1.5:-2,1.5-\<LLN:-1,LLN:0. Potentially clinically significant increase or decrease was defined as Baseline grade 0,1,-1 and post-baseline grade \>1, \<-1 or Baseline grade \>1,\<-1 and post-baseline grade \>or\<Baseline grade.

    Time frame: From first dose of study drug up to 14 days post last dose (up to approximately 37 months)

  20. Phase A and B: Percentage of Participants With Aquaretic Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Aquaretic AEs included Medical Dictionary for Regulatory Activities \[MedDRA\] preferred terms of thirst, polyuria (production of large volumes of dilute urine), nocturia (need to wake up to urinate at night), pollakiuria (abnormally frequent urination), and polydipsia (excessive thirst). As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).

    Time frame: From first dose of study drug up to 14 days post last dose (up to approximately 37 months)

07

Results

Posted Jan 3, 2023

Participant flow

Participants took part in the study at 18 sites in Belgium, Germany, Italy, and the United Kingdom from 23 September 2016 to 17 November 2021.

Phase A: Double-blind Period (12 Months)
Participant flow — Phase A: Double-blind Period (12 Months)
MilestonePhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
Started484300
Dense pharmacokinetic/pharmacodynamic (pk/pd) population12800
Completed444000
Not completed4300
Withdrew: Adverse events1000
Withdrew: Physician decision0200
Withdrew: Withdrawal by subject3100
Phase B: Open-label Period (24 Months)
Participant flow — Phase B: Open-label Period (24 Months)
MilestonePhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
Started004239
Completed003633
Not completed0066
Withdrew: Adverse events0002
Withdrew: Withdrawal by subject0043
Withdrew: Reason not specified0021

Outcome measures

PrimaryPhase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose)

Urine osmolality is a measure of urine concentration, measured by osmometer, which evaluates the freezing point depression of a solution and supplies results as milliosmoles per kilogram of water. Spot urine osmolality was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.

Time frame:
Baseline, and Week 1 of Phase A
Reported as:
Mean · milliosmoles per kilogram (mOsm/kg)
Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose)
milliosmoles per kilogram (mOsm/kg)Phase A: TolvaptanPhase A: Placebo
Baseline635 ± 252646 ± 250
Change From Baseline at Week 1, Phase A-386 ± 284-93 ± 332
PrimaryPhase A: Change From Baseline in Specific Gravity (Pre-morning Dose)

Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Spot urine sample for determination of specific gravity was collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.

Time frame:
Baseline, and Week 1 of Phase A
Reported as:
Mean · ratio
Phase A: Change From Baseline in Specific Gravity (Pre-morning Dose)
ratioPhase A: TolvaptanPhase A: Placebo
Baseline1.017 ± 0.0061.017 ± 0.006
Change From Baseline at Week 1, Phase A-0.009 ± 0.007-0.002 ± 0.008
SecondaryPhase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI)

htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.

Time frame:
Baseline, and Month 12 of Phase A
Reported as:
Mean · percent change
Phase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI)
percent changePhase A: TolvaptanPhase A: Placebo
Phase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI)2.28 ± 8.756.11 ± 7.48
SecondaryPhase A and B: Mean 24-hour Fluid Balance Prior to Week 1

Participants were instructed to record all fluid taken and all urine output for the 24-hour period.

Time frame:
Prior to Week 1 in Phase A and B
Reported as:
Mean · milliliter
Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1
milliliterPhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
Phase A and B: Mean 24-hour Fluid Balance Prior to Week 131 ± 1978241 ± 867138 ± 1382207 ± 1355
SecondaryPhase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A

Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points. The units for the data reported are milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). The baseline was the evaluation done at Week 1 in Phase A for this outcome measure.

Time frame:
Phase A Baseline, Months 1, 6, and 12
Reported as:
Mean · mL/min/1.73 m^2
Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A
mL/min/1.73 m^2Phase A: TolvaptanPhase A: Placebo
Baseline93.9 ± 18.7102.1 ± 15.4
Change From Baseline at Month 1, Phase A2.8 ± 10.7-1.9 ± 8.8
Change From Baseline at Month 6, Phase A4.6 ± 10.1-2.5 ± 11.1
Change From Baseline at Month 12, Phase A2.6 ± 10.7-3.2 ± 10.9
SecondaryPhase B: Change From Phase B Baseline in Renal Function (eGFR by Schwartz Formula) at Each Clinic Visit in Phase B

Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points.

Time frame:
Phase B Baseline, Week 1, Months 1, 6, 12, 18, and 24
Reported as:
Mean · mL/min/1.73 m^2
Phase B: Change From Phase B Baseline in Renal Function (eGFR by Schwartz Formula) at Each Clinic Visit in Phase B
mL/min/1.73 m^2Phase B: Prior TolvaptanPhase B: Prior Placebo
Phase B Baseline97.0 ± 17.198.5 ± 14.1
Change From Phase B Baseline at Week 1, Phase B-1.7 ± 10.4-6.7 ± 8.0
Change From Phase B Baseline at Month 1, Phase B-0.9 ± 10.2-4.8 ± 9.0
Change From Phase B Baseline at Month 6, Phase B-4.2 ± 9.6-6.4 ± 7.9
Change From Phase B Baseline at Month 12, Phase B-5.6 ± 11.1-7.2 ± 9.3
Change From Phase B Baseline at Month 18, Phase B-3.5 ± 9.8-9.0 ± 10.9
Change From Phase B Baseline at Month 24, Phase B-5.2 ± 9.4-10.3 ± 11.0
SecondaryPhase B: Percent Change From Phase B Baseline in htTKV as Measured by MRI at Month 12 and Month 24

htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.

Time frame:
Phase B Baseline, Months 12 and 24
Reported as:
Mean · percent change
Phase B: Percent Change From Phase B Baseline in htTKV as Measured by MRI at Month 12 and Month 24
percent changePhase B: Prior TolvaptanPhase B: Prior Placebo
Percent Change From Phase B Baseline at Month 12, Phase B7.68 ± 9.673.09 ± 8.97
Percent Change From Phase B Baseline at Month 24 Phase B13.55 ± 12.887.35 ± 9.57
SecondaryPhase A: 24-hour Urine Volume

Urine volume refers to the quantity of urine produced per unit of time.

Time frame:
24 hours post dose after Month 1 on study medication in Phase A
Reported as:
Mean · milliliter per 24 hours post dose
Phase A: 24-hour Urine Volume
milliliter per 24 hours post dosePhase A: TolvaptanPhase A: Placebo
Phase A: 24-hour Urine Volume7171 ± 28102529 ± 2164
SecondaryPhase A: 24-hour Fluid Intake

Daily fluid intake (total water) is defined as the amount of water consumed from foods, plain drinking water, and other beverages.

Time frame:
24 hours post dose after Month 1 on study medication in Phase A
Reported as:
Mean · milliliter
Phase A: 24-hour Fluid Intake
milliliterPhase A: TolvaptanPhase A: Placebo
Phase A: 24-hour Fluid Intake7486 ± 23503156 ± 1775
SecondaryPhase A: 24-hour Fluid Balance

Fluid balance is a term used to describe the balance of the input and output of fluids in the body to allow metabolic processes to function correctly.

Time frame:
24 hours post dose after Month 1 on study medication in Phase A
Reported as:
Mean · milliliter
Phase A: 24-hour Fluid Balance
milliliterPhase A: TolvaptanPhase A: Placebo
Phase A: 24-hour Fluid Balance53 ± 1894230 ± 1254
SecondaryPhase A: 24-hour Sodium Clearance

Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.

Time frame:
24 hours post dose after Month 1 on study medication in Phase A
Reported as:
Mean · milliliter per minute (mL/min)
Phase A: 24-hour Sodium Clearance
milliliter per minute (mL/min)Phase A: TolvaptanPhase A: Placebo
Total Daily Dose: 37.5 mg0.8 ± 0.3—
Total Daily Dose: 45 mg0.7 ± 0.3—
Total Daily Dose: 60 mg0.9 ± 0.3—
Total Daily Dose: Placebo—0.7 ± 0.5
SecondaryPhase A: 24-hour Creatinine Clearance

Creatinine is produced from the metabolism of protein, when muscles burn energy. Most creatinine is filtered out of the blood by the kidneys and excreted in urine. The creatinine clearance value is determined by measuring the concentration of endogenous creatinine (that which is produced by the body) in both plasma and urine. Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.

Time frame:
24 hours post dose after Month 1 on study medication in Phase A
Reported as:
Mean · mL/min
Phase A: 24-hour Creatinine Clearance
mL/minPhase A: TolvaptanPhase A: Placebo
Total Daily Dose: 22.5 mg124.6 ± NA—
Total Daily Dose: 37.5 mg148.5 ± 23.4—
Total Daily Dose: 45 mg95.0 ± 10.1—
Total Daily Dose: 60 mg123.7 ± 23.2—
Total Daily Dose: Placebo—105.1 ± 51.7
SecondaryPhase A: 24-hour Free Water Clearance

Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.

Time frame:
24 hours post dose after Month 1 on study medication in Phase A
Reported as:
Mean · mL/min
Phase A: 24-hour Free Water Clearance
mL/minPhase A: TolvaptanPhase A: Placebo
Total Daily Dose: 37.5 mg2.3 ± 0.9—
Total Daily Dose: 45 mg2.6 ± 0.9—
Total Daily Dose: 60 mg3.0 ± 1.2—
Total Daily Dose: Placebo—0.1 ± 1.2
SecondaryPhase A: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations

Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.

Time frame:
At Baseline, Months 6 and 12 of Phase A
Reported as:
Number · percentage of participants
Phase A: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations
percentage of participantsPhase A: TolvaptanPhase A: Placebo
Female (>=4 to <12 Years): Baseline- Stage 16.311.6
Female (>=4 to <12 Years): Baseline- Stage 30.02.3
Female (>=4 to <12 Years): Month 6, Phase A- Stage 16.39.3
Female (>=4 to <12 Years): Month 6, Phase A- Stage 20.02.3
Female (>=4 to <12 Years): Month 6, Phase A- Stage 40.02.3
Female (>=4 to <12 Years): Month 12, Phase A- Stage 14.27.0
Female (>=4 to <12 Years): Month 12, Phase A- Stage 20.02.3
Female (>=4 to <12 Years): Month 12, Phase A- Stage 40.02.3
Male (>=4 to <12 Years): Baseline- Stage 116.74.7
Male (>=4 to <12 Years): Baseline- Stage 20.04.7
Male (>=4 to <12 Years): Baseline- Stage 32.10.0
Male (>=4 to <12 Years): Month 6, Phase A- Stage 116.77.0
Male (>=4 to <12 Years): Month 6, Phase A- Stage 22.10.0
Male (>=4 to <12 Years): Month 6, Phase A- Stage 32.14.7
Male (>=4 to <12 Years): Month 12, Phase A- Stage 114.64.7
Male (>=4 to <12 Years): Month 12, Phase A- Stage 24.22.3
Male (>=4 to <12 Years): Month 12, Phase A- Stage 30.04.7
Male (>=4 to <12 Years): Month 12, Phase A- Stage 42.10.0
Female (>=12 to <15 Years): Baseline- Stage 12.10.0
Female (>=12 to <15 Years): Baseline- Stage 20.04.7
Female (>=12 to <15 Years): Baseline- Stage 32.12.3
Female (>=12 to <15 Years): Baseline- Stage 44.20.0
Female (>=12 to <15 Years): Baseline- Stage 510.47.0
Female (>=12 to <15 Years): Month 6, Phase A- Stage 20.02.3
Female (>=12 to <15 Years): Month 6, Phase A- Stage 30.02.3
Female (>=12 to <15 Years): Month 6, Phase A- Stage 42.10.0
Female (>=12 to <15 Years): Month 6, Phase A- Stage 512.57.0
Female (>=12 to <15 Years): Month 12, Phase A- Stage 20.02.3
Female (>=12 to <15 Years): Month 12, Phase A- Stage 30.02.3
Female (>=12 to <15 Years): Month 12, Phase A- Stage 40.04.7
Female (>=12 to <15 Years): Month 12, Phase A- Stage 514.69.3
Male (>=12 to <15 Years): Baseline- Stage 26.34.7
Male (>=12 to <15 Years): Baseline- Stage 34.24.7
Male (>=12 to <15 Years): Baseline- Stage 42.14.7
Male (>=12 to <15 Years): Baseline- Stage 52.12.3
Male (>=12 to <15 Years): Month 6, Phase A- Stage 24.22.3
Male (>=12 to <15 Years): Month 6, Phase A- Stage 34.22.3
Male (>=12 to <15 Years): Month 6, Phase A- Stage 44.24.7
Male (>=12 to <15 Years): Month 6, Phase A- Stage 52.12.3
Male (>=12 to <15 Years): Month 12, Phase A- Stage 20.02.3
Male (>=12 to <15 Years): Month 12, Phase A- Stage 32.10.0
Male (>=12 to <15 Years): Month 12, Phase A- Stage 48.37.0
Male (>=12 to <15 Years): Month 12, Phase A- Stage 54.22.3
Male (>=12 to <15 Years): End of Treatment- Stage 52.12.3
Female (>=15 to <18 Years): Baseline- Stage 42.10.0
Female (>=15 to <18 Years): Baseline- Stage 512.518.6
Female (>=15 to <18 Years): Month 6, Phase A- Stage 42.10.0
Female (>=15 to <18 Years): Month 6, Phase A- Stage 512.516.3
Female (>=15 to <18 Years): Month 12, Phase A- Stage 42.10.0
Female (>=15 to <18 Years): Month 12, Phase A- Stage 514.616.3
Female (>=15 to <18 Years): End of Treatment- Stage 50.02.3
Male (>=15 to <18 Years): Baseline- Stage 42.14.7
Male (>=15 to <18 Years): Baseline- Stage 516.714.0
Male (>=15 to <18 Years): Month 6, Phase A- Stage 42.12.3
Male (>=15 to <18 Years): Month 6, Phase A- Stage 514.616.3
Male (>=15 to <18 Years): Month 12, Phase A- Stage 42.10.0
Male (>=15 to <18 Years): Month 12, Phase A- Stage 514.618.6
Male (>=15 to <18 Years): End of Treatment- Stage 52.10.0
SecondaryPhase B: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations

Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.

Time frame:
At Baseline, Months 6, 12, 18, and 24 of Phase B
Reported as:
Number · percentage of participants
Phase B: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations
percentage of participantsPhase B: Prior TolvaptanPhase B: Prior Placebo
Female (>=4 to <12 Years): Phase B Baseline- Stage 17.110.3
Female (>=4 to <12 Years): Phase B Baseline- Stage 20.02.6
Female (>=4 to <12 Years): Phase B Baseline- Stage 40.02.6
Female (>=4 to <12 Years): Month 6, Phase B- Stage 14.87.7
Female (>=4 to <12 Years): Month 6, Phase B- Stage 20.02.6
Female (>=4 to <12 Years): Month 6, Phase B- Stage 40.02.6
Female (>=4 to <12 Years): Month 12, Phase B- Stage 14.87.7
Female (>=4 to <12 Years): Month 12, Phase B- Stage 20.02.6
Female (>=4 to <12 Years): Month 12, Phase B- Stage 30.02.6
Female (>=4 to <12 Years): Month 12, Phase B- Stage 40.02.6
Female (>=4 to <12 Years): Month 18, Phase B- Stage 14.82.6
Female (>=4 to <12 Years): Month 18, Phase B- Stage 20.07.7
Female (>=4 to <12 Years): Month 18, Phase B- Stage 40.02.6
Female (>=4 to <12 Years): Month 24, Phase B- Stage 12.42.6
Female (>=4 to <12 Years): Month 24, Phase B- Stage 22.45.1
Female (>=4 to <12 Years): Month 24, Phase B- Stage 30.02.6
Female (>=4 to <12 Years): Month 24, Phase B- Stage 40.02.6
Male (>=4 to <12 Years): Phase B Baseline- Stage 111.95.1
Male (>=4 to <12 Years): Phase B Baseline- Stage 24.82.6
Male (>=4 to <12 Years): Phase B Baseline- Stage 30.05.1
Male (>=4 to <12 Years): Phase B Baseline- Stage 42.40.0
Male (>=4 to <12 Years): Month 6, Phase B- Stage 19.52.6
Male (>=4 to <12 Years): Month 6, Phase B- Stage 22.42.6
Male (>=4 to <12 Years): Month 6, Phase B- Stage 32.42.6
Male (>=4 to <12 Years): Month 6, Phase B- Stage 42.42.6
Male (>=4 to <12 Years): Month 12, Phase B- Stage 19.52.6
Male (>=4 to <12 Years): Month 12, Phase B- Stage 22.40.0
Male (>=4 to <12 Years): Month 12, Phase B- Stage 32.45.1
Male (>=4 to <12 Years): Month 12, Phase B- Stage 42.42.6
Male (>=4 to <12 Years): Month 18, Phase B- Stage 14.82.6
Male (>=4 to <12 Years): Month 18, Phase B- Stage 22.40.0
Male (>=4 to <12 Years): Month 18, Phase B- Stage 30.05.1
Male (>=4 to <12 Years): Month 18, Phase B- Stage 44.80.0
Male (>=4 to <12 Years): Month 18, Phase B- Stage 50.02.6
Male (>=4 to <12 Years): Month 24, Phase B- Stage 14.80.0
Male (>=4 to <12 Years): Month 24, Phase B- Stage 24.80.0
Male (>=4 to <12 Years): Month 24, Phase B- Stage 32.45.1
Male (>=4 to <12 Years): Month 24, Phase B- Stage 42.40.0
Male (>=4 to <12 Years): Month 24, Phase B- Stage 52.42.6
Female (>=12 to <15 Years): Phase B Baseline- Stage 20.02.6
Female (>=12 to <15 Years): Phase B Baseline- Stage 30.02.6
Female (>=12 to <15 Years): Phase B Baseline- Stage 40.05.1
Female (>=12 to <15 Years): Phase B Baseline- Stage 516.710.3
Female (>=12 to <15 Years): Month 6, Phase B- Stage 30.05.1
Female (>=12 to <15 Years): Month 6, Phase B- Stage 40.05.1
Female (>=12 to <15 Years): Month 6, Phase B-Stage 516.710.3
Female (>=12 to <15 Years): Month 12, Phase B- Stage 40.05.1
Female (>=12 to <15 Years): Month 12, Phase B- Stage 514.310.3
Female (>=12 to <15 Years): Month 18, Phase B- Stage 40.02.6
Female (>=12 to <15 Years): Month 18, Phase B- Stage 511.910.3
Female (>=12 to <15 Years): Month 24, Phase B- Stage 40.05.1
Female (>=12 to <15 Years): Month 24, Phase B- Stage 59.510.3
Female (>=12 to <15 Years): End of Treatment, Phase B- Stage 40.02.6
Female (>=12 to <15 Years): End of Treatment, Phase B- Stage 57.12.6
Male (>=12 to <15 Years): Phase B Baseline- Stage 20.02.6
Male (>=12 to <15 Years): Phase B Baseline- Stage 32.40.0
Male (>=12 to <15 Years): Phase B Baseline- Stage 49.57.7
Male (>=12 to <15 Years): Phase B Baseline- Stage 54.82.6
Male (>=12 to <15 Years): Month 6, Phase B- Stage 20.02.6
Male (>=12 to <15 Years): Month 6, Phase B- Stage 32.40.0
Male (>=12 to <15 Years): Month 6, Phase B- Stage 44.85.1
Male (>=12 to <15 Years): Month 6, Phase B- Stage 54.82.6
Male (>=12 to <15 Years): Month 12, Phase B- Stage 20.02.6
Male (>=12 to <15 Years): Month 12, Phase B- Stage 47.15.1
Male (>=12 to <15 Years): Month 12, Phase B- Stage 57.15.1
Male (>=12 to <15 Years): Month 18, Phase B- Stage 20.02.6
Male (>=12 to <15 Years): Month 18, Phase B- Stage 44.80.0
Male (>=12 to <15 Years): Month 18, Phase B- Stage 59.57.7
Male (>=12 to <15 Years): Month 24, Phase B- Stage 20.02.6
Male (>=12 to <15 Years): Month 24, Phase B- Stage 44.80.0
Male (>=12 to <15 Years): Month 24, Phase B- Stage 59.510.3
Male (>=12 to <15 Years): End of Treatment, Phase B- Stage 50.02.6
Female (>=15 to <18 Years): Phase B Baseline- Stage 42.40.0
Female (>=15 to <18 Years): Phase B Baseline- Stage 516.715.4
Female (>=15 to <18 Years): Month 6, Phase B- Stage 42.40.0
Female (>=15 to <18 Years): Month 6, Phase B- Stage 516.712.8
Female (>=15 to <18 Years): Month 12, Phase B- Stage 42.40.0
Female (>=15 to <18 Years): Month 12, Phase B- Stage 516.712.8
Female (>=15 to <18 Years): Month 18, Phase B- Stage 42.40.0
Female (>=15 to <18 Years): Month 18, Phase B- Stage 516.712.8
Female (>=15 to <18 Years): Month 24, Phase B- Stage 42.40.0
Female (>=15 to <18 Years): Month 24, Phase B- Stage 516.712.8
Female (>=15 to <18 Years): End of Treatment, Phase B- Stage 50.05.1
Male (>=15 to <18 Years): Phase B Baseline- Stage 42.40.0
Male (>=15 to <18 Years): Phase B Baseline- Stage 516.720.5
Male (>=15 to <18 Years): Month 6, Phase B- Stage 519.017.9
Male (>=15 to <18 Years): Month 12, Phase B- Stage 516.717.9
Male (>=15 to <18 Years): Month 18, Phase B- Stage 516.715.4
Male (>=15 to <18 Years): Month 24, Phase B- Stage 516.712.8
Male (>=15 to <18 Years): End of Treatment, Phase B- Stage 54.87.7
SecondaryPhase A: Change From Baseline in Growth Percentile by Gender and Age

The growth percentile was based on the assessment of height and weight.

Time frame:
At Baseline, Months 6 and 12 of Phase A
Reported as:
Mean · growth percentile
Phase A: Change From Baseline in Growth Percentile by Gender and Age
growth percentilePhase A: TolvaptanPhase A: Placebo
Female Participants with Age >=15 to <18 Years - Baseline, Phase A62 ± 2860 ± 34
Change From Baseline in Female Participants with Age >=15 to <18 Years - Month 6, Phase A2 ± 18-2 ± 12
Change From Baseline in Female Participants with Age >=15 to <18 Years - Month 12, Phase A7 ± 10-5 ± 11
Male Participants with Age >=15 to <18 Years - Baseline, Phase A56 ± 2973 ± 18
Change From Baseline in Male Participants with Age >=15 to <18 Years - Month 6, Phase A12 ± 16-1 ± 30
Change From Baseline in Male Participants with Age >=15 to <18 Years - Month 12, Phase A2 ± 37-3 ± 25
Female Participants with Age >=12 to <15 Years - Baseline, Phase A71 ± 2072 ± 29
Change From Baseline in Female Participants with Age >=12 to <15 Years - Month 6, Phase A-2 ± 12-20 ± 21
Change From Baseline in Female Participants with Age >=12 to <15 Years - Month 12, Phase A-11 ± 9-18 ± 27
Male Participants with Age >=12 to <15 Years - Baseline, Phase A70 ± 2176 ± 24
Change From Baseline in Male Participants with Age >=12 to <15 Years - Month 6, Phase A-7 ± 13-13 ± 38
Change From Baseline in Male Participants with Age >=12 to <15 Years - Month 12, Phase A0 ± 208 ± 17
Female Participants with Age 4 to <=11 Years - Baseline, Phase A71 ± 2557 ± 14
Change From Baseline in Female Participants with Age 4 to <=11 Years - Month 6, Phase A-1 ± 34 ± 16
Change From Baseline in Female Participants with Age 4 to <=11 Years - Month 12, Phase A7 ± 152 ± 18
Male Participants with Age 4 to <=11 Years - Baseline, Phase A57 ± 3163 ± 19
Change From Baseline in Male Participants with Age 4 to <=11 Years - Month 6, Phase A4 ± 160 ± 0
Change From Baseline in Male Participants with Age 4 to <=11 Years - Month 12, Phase A1 ± 31 ± 4
SecondaryPhase B: Change From Baseline in Growth Percentile by Gender and Age

The growth percentile was based on the assessment of height and weight.

Time frame:
At Baseline, Months 6, 12, 18, and 24 of Phase B
Reported as:
Mean · growth percentile
Phase B: Change From Baseline in Growth Percentile by Gender and Age
growth percentilePhase B: Prior TolvaptanPhase B: Prior Placebo
Female Participants with Age >=15 to <18 Years - Phase B Baseline69 ± 3246 ± 28
Change From Baseline Female Participants with Age >=15 to <18 Years - Month 6, Phase B-7 ± 1712 ± 21
Change From Baseline Female Participants with Age >=15 to <18 Years - Month 12, Phase B0 ± 720 ± 18
Change From Baseline Female Participants with Age >=15 to <18 Years - Month 18, Phase B-2 ± 210 ± 9
Change From Baseline Female Participants with Age >=15 to <18 Years - Month 24, Phase B6 ± 1616 ± 20
Male Participants with Age >=15 to <18 Years - Phase B Baseline60 ± 3469 ± 18
Change From Baseline Male Participants with Age >=15 to <18 Years - Month 6, Phase B-13 ± 531 ± 2
Change From Baseline Male Participants with Age >=15 to <18 Years - Month 12, Phase B-8 ± 478 ± 11
Change From Baseline Male Participants with Age >=15 to <18 Years - Month 18, Phase B16 ± 65-4 ± 25
Change From Baseline Male Participants with Age >=15 to <18 Years - Month 24, Phase B-2 ± 50-11 ± 25
Female Participants with Age >=12 to <15 Years - Phase B Baseline62 ± 2454 ± 34
Change From Baseline Female Participants with Age >=12 to <15 Years - Month 6, Phase B3 ± 613 ± 18
Change From Baseline Female Participants with Age >=12 to <15 Years - Month 12, Phase B12 ± 2012 ± 23
Change From Baseline Female Participants with Age >=12 to <15 Years - Month 18, Phase B5 ± 910 ± 22
Change From Baseline Female Participants with Age >=12 to <15 Years - Month 24, Phase B1 ± 313 ± 18
Male Participants with Age >=12 to <15 Years - Phase B Baseline67 ± 2677 ± 23
Change From Baseline Male Participants with Age >=12 to <15 Years - Month 6, Phase B1 ± 10-15 ± 38
Change From Baseline Male Participants with Age >=12 to <15 Years - Month 12, Phase B4 ± 16-23 ± 37
Change From Baseline Male Participants with Age >=12 to <15 Years - Month 18, Phase B-4 ± 14-22 ± 40
Change From Baseline Male Participants with Age >=12 to <15 Years - Month 24, Phase B-8 ± 15-18 ± 36
Female Participants with Age 4 to <=11 Years - Phase B Baseline78 ± 1959 ± 22
Change From Baseline Female Participants with Age 4 to <=11 Years - Month 6, Phase B-2 ± 22 ± 12
Change From Baseline Female Participants with Age 4 to <=11 Years - Month 12, Phase B5 ± 81 ± 12
Change From Baseline Female Participants with Age 4 to <=11 Years - Month 18, Phase B-5 ± 62 ± 23
Change From Baseline Female Participants with Age 4 to <=11 Years - Month 24, Phase B-4 ± 510 ± 21
Male Participants with Age 4 to <=11 Years - Phase B Baseline65 ± 3064 ± 21
Change From Baseline Male Participants with Age 4 to <=11 Years - Month 6, Phase B0 ± 131 ± 2
Change From Baseline Male Participants with Age 4 to <=11 Years - Month 12, Phase B3 ± 204 ± 8
Change From Baseline Male Participants with Age 4 to <=11 Years - Month 18, Phase B-4 ± 122 ± 9
Change From Baseline Male Participants with Age 4 to <=11 Years - Month 24, Phase B0 ± 1821 ± 23
SecondaryPhase A: Change From Baseline in Creatinine Value

Phase A Baseline is the last pre-dose evaluation. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan and Phase A: Placebo)

Time frame:
Baseline, Week 1, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, Follow Up Day 7, End of Treatment, and Last Visit
Reported as:
Mean · milligrams per deciliter (mg/dL)
Phase A: Change From Baseline in Creatinine Value
milligrams per deciliter (mg/dL)Phase A: TolvaptanPhase A: Placebo
Baseline0.70 ± 0.160.67 ± 0.12
Change From Baseline at Week 10.04 ± 0.09-0.01 ± 0.06
Change From Baseline at Month 10.01 ± 0.080.01 ± 0.06
Change From Baseline at Month 20.01 ± 0.090.00 ± 0.07
Change From Baseline at Month 30.00 ± 0.110.01 ± 0.06
Change From Baseline at Month 40.00 ± 0.09-0.01 ± 0.07
Change From Baseline at Month 50.01 ± 0.090.01 ± 0.06
Change From Baseline at Month 60.01 ± 0.100.02 ± 0.07
Change From Baseline at Month 70.01 ± 0.100.02 ± 0.06
Change From Baseline at Month 80.01 ± 0.110.02 ± 0.07
Change From Baseline at Month 90.04 ± 0.110.01 ± 0.07
Change From Baseline at Month 100.01 ± 0.100.03 ± 0.07
Change From Baseline at Month 110.02 ± 0.110.04 ± 0.08
Change From Baseline at Month 120.02 ± 0.090.02 ± 0.06
Change From Baseline at Follow Up Day 70.09 ± NA-0.02 ± NA
Change From Baseline at End of Treatment0.03 ± 0.100.03 ± 0.04
Change From Baseline at Last Visit0.03 ± 0.090.02 ± 0.06
SecondaryPhase B: Change From Baseline in Creatinine Value

Phase B Baseline is the last evaluation prior to the first dose in Phase B. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase B: Prior Tolvaptan and Phase B: Prior Placebo).

Time frame:
Baseline, Week 1, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, Follow Up Day 7, End of Treatment, and Last Visit
Reported as:
Mean · mg/dL
Phase B: Change From Baseline in Creatinine Value
mg/dLPhase B: Prior TolvaptanPhase B: Prior Placebo
Baseline0.73 ± 0.170.69 ± 0.13
Change From Baseline at Week 10.01 ± 0.060.04 ± 0.06
Change From Baseline at Month 10.01 ± 0.070.04 ± 0.06
Change From Baseline at Month 20.02 ± 0.070.04 ± 0.07
Change From Baseline at Month 30.02 ± 0.070.04 ± 0.07
Change From Baseline at Month 40.04 ± 0.060.05 ± 0.07
Change From Baseline at Month 50.03 ± 0.060.07 ± 0.07
Change From Baseline at Month 60.03 ± 0.070.06 ± 0.07
Change From Baseline at Month 70.04 ± 0.070.06 ± 0.07
Change From Baseline at Month 80.05 ± 0.080.07 ± 0.07
Change From Baseline at Month 90.07 ± 0.110.09 ± 0.13
Change From Baseline at Month 100.06 ± 0.070.06 ± 0.07
Change From Baseline at Month 110.05 ± 0.070.08 ± 0.08
Change From Baseline at Month 120.06 ± 0.120.07 ± 0.08
Change From Baseline at Month 130.04 ± 0.080.08 ± 0.08
Change From Baseline at Month 140.08 ± 0.070.08 ± 0.08
Change From Baseline at Month 150.06 ± 0.070.06 ± 0.08
Change From Baseline at Month 160.05 ± 0.080.08 ± 0.09
Change From Baseline at Month 170.07 ± 0.080.08 ± 0.09
Change From Baseline at Month 180.05 ± 0.090.09 ± 0.07
Change From Baseline at Month 190.06 ± 0.100.09 ± 0.10
Change From Baseline at Month 200.04 ± 0.080.11 ± 0.08
Change From Baseline at Month 210.09 ± 0.120.09 ± 0.10
Change From Baseline at Month 220.06 ± 0.080.09 ± 0.10
Change From Baseline at Month 230.07 ± 0.060.12 ± 0.08
Change From Baseline at Month 240.07 ± 0.080.12 ± 0.10
Change From Baseline at Follow Up Day 7-0.01 ± 0.020.14 ± 0.08
Change From Baseline at End of Treatment-0.01 ± 0.110.02 ± 0.08
Change From Baseline at Last Visit0.05 ± 0.090.10 ± 0.08
SecondaryPhase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Vital Signs

Vital sign measurements included measurements of respiratory rate, blood pressure, body temperature and pulse. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. Only those categories with at least one participant with event are reported. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).

Time frame:
From first dose of study drug up to 14 days post last dose (up to approximately 37 months)
Reported as:
Number · percentage of participants
Phase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
percentage of participantsPhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
Pulse Rate (Beats per Minute [BPM]) <=50 and Decrease from Baseline >=150.02.30.05.3
Systolic Blood Pressure (millimetre of mercury [mmHg]) >=130 and Increase from Baseline >=202.10.00.00.0
Systolic Blood Pressure (mmHg) <=120 and Decrease from Baseline >=204.27.09.510.3
Systolic Blood Pressure (mmHg) >=144 and Increase from Baseline >=202.12.30.02.6
Diastolic Blood Pressure (mmHg) <=50 and Decrease from Baseline >=154.27.09.50.0
Diastolic Blood Pressure (mmHg) >=86 and Increase from Baseline >=150.00.07.10.0
Diastolic Blood Pressure (mmHg) <=80 and Decrease from Baseline >=1512.518.616.712.8
Diastolic Blood Pressure (mmHg) >=92 and Increase from Baseline >=150.04.74.82.6
SecondaryPhase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Test Results Including Liver Function Tests (LFTs)

Laboratory parameters=haematology,chemistry,urinalysis,\& LFTs.Criteria for laboratory abnormalities along with their test result grade=Increased creatinine level: Baseline(BSL):Grade 0,\>BSL-1.5xBSL:1,\>1.5-3xBSL:2,\>3-6xBSL:3,\>6xBSL:4.Decreased glucose level: \<30:-4,30-\<40:-3, 40-\<55:-2, 55-\<65:-1,\>=65:0; Increased:\<=115:0,\>115-160:1,\>160-250:2,\>250-500:3,\>500:4.Decreased potassium level: \<2.5:-4,2.5-\<3:-3,3-\<lower limit of normal(LLN):-1,LLN:0; Increased:upper limit of normal(ULN):0,\>ULN-5.5:1,\>5.5-6:2,\>6-7:3,\>7:4.Decreased sodium level: \<120:-4,120-124:-3,125-129:-2,130-135:-1,\>=136:0; Increased:\<=145:0,146-150:1,151-155:2,156-160:3,\>160:4. Increased triglyceride level:ULN:0,\>ULN-2.5xULN:1,\>2.5-5xULN:2,\>5-6xULN:3,\>6xULN:4. Decreased Neutrophils:\<0.5:-4,0.5-\<1:-3,1-\<1.5:-2,1.5-\<LLN:-1,LLN:0. Potentially clinically significant increase or decrease was defined as Baseline grade 0,1,-1 and post-baseline grade \>1, \<-1 or Baseline grade \>1,\<-1 and post-baseline grade \>or\<Baseline grade.

Time frame:
From first dose of study drug up to 14 days post last dose (up to approximately 37 months)
Reported as:
Number · percentage of participants
Phase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Test Results Including Liver Function Tests (LFTs)
percentage of participantsPhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
Increase in Creatinine Level (mg/dL)8.30.07.17.7
Decrease in Glucose Level (mg/dL)0.02.60.02.9
Increase in Potassium Level (milliequivalents per deciliter [mEq/dL])2.10.00.02.6
Increase in Sodium Level (mEq/dL)0.00.00.02.6
Increase in Triglyceride Level (mg/dL)0.00.03.10.0
Decrease in Neutrophils (10^9/L)0.04.95.02.6
SecondaryPhase A and B: Percentage of Participants With Aquaretic Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Aquaretic AEs included Medical Dictionary for Regulatory Activities \[MedDRA\] preferred terms of thirst, polyuria (production of large volumes of dilute urine), nocturia (need to wake up to urinate at night), pollakiuria (abnormally frequent urination), and polydipsia (excessive thirst). As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).

Time frame:
From first dose of study drug up to 14 days post last dose (up to approximately 37 months)
Reported as:
Number · percentage of participants
Phase A and B: Percentage of Participants With Aquaretic Adverse Events (AEs)
percentage of participantsPhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
Phase A and B: Percentage of Participants With Aquaretic Adverse Events (AEs)64.616.314.348.7

Adverse events

Collected over From the first dose of study drug up to 14 days post last dose (up to approximately 37 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase A: Tolvaptan0/48 (0%)1/48 (2.1%)45/48 (93.8%)
Phase A: Placebo0/43 (0%)6/43 (14%)42/43 (97.7%)
Phase B: Prior Tolvaptan0/42 (0%)7/42 (16.7%)38/42 (90.5%)
Phase B: Prior Placebo0/39 (0%)8/39 (20.5%)39/39 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
Aspartate aminotransferase increasedInvestigations0/480/430/422/39
COVID-19Infections and infestations0/480/432/420/39
Abdominal painGastrointestinal disorders0/480/431/421/39
Arthritis bacterialInfections and infestations0/480/430/421/39
Expired product administeredInjury, poisoning and procedural complications0/480/430/421/39
Alanine aminotransferase increasedInvestigations0/480/431/421/39
Heart rate increasedInvestigations0/480/430/421/39
SARS-COV-2 test positiveInvestigations0/480/431/421/39
Eating disorderPsychiatric disorders0/480/430/421/39
Renal impairmentRenal and urinary disorders0/480/431/421/39
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPhase A: TolvaptanPhase A: PlaceboPhase B: Prior TolvaptanPhase B: Prior Placebo
HeadacheNervous system disorders16/4821/4315/4217/39
NasopharyngitisInfections and infestations10/4814/4311/4213/39
PolyuriaRenal and urinary disorders13/482/432/4213/39
Abdominal painGastrointestinal disorders6/483/434/4212/39
RhinitisInfections and infestations3/483/4311/424/39
VomitingGastrointestinal disorders7/4810/435/427/39
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/486/439/427/39
CoughRespiratory, thoracic and mediastinal disorders7/485/437/428/39
PyrexiaGeneral disorders4/483/438/427/39
Blood creatinine increasedInvestigations9/482/437/425/39

Baseline characteristics

The Randomized Sample included all participants who were randomized in the trial.

Age, Continuous
Age, Continuous(years)Phase A: TolvaptanPhase A: PlaceboTotal
Mean12.9 ± 3.212.8 ± 2.812.9 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)Phase A: TolvaptanPhase A: PlaceboTotal
Female212344
Male272047
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase A: TolvaptanPhase A: PlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino474289
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase A: TolvaptanPhase A: PlaceboTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American011
White464288
More than one race000
Unknown or Not Reported000
08

Study locations

20 sites
  • Gent, Oost-Vlaanderen 9000, Belgium
  • Leuven, Vlaams Brabant 3000, Belgium
  • Brussels, 1200, Belgium
  • Bruxelles, 1020, Belgium
  • Montegnee, 4420, Belgium
  • Cologne, 50937, Germany
  • Hamburg, 20246, Germany
  • Hannover, 30625, Germany
  • Heidelberg, 69120, Germany
  • Leipzig, 04103, Germany
  • Tuebingen, 72076, Germany
  • Milano, 20122, Italy
  • Napoli, 80129, Italy
  • Napoli, 80131, Italy
  • Pavia, 27100, Italy
  • Birmingham, B4 6NH, United Kingdom
  • London, SE1 7EH, United Kingdom
  • London, WC1N 3JH, United Kingdom
  • Manchester, M13 9WL, United Kingdom
  • Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Liu F, Feng C, Shen H, Fu H, Mao J. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where? Kidney Dis (Basel). 2021 Sep;7(5):343-349. doi: 10.1159/000517186. Epub 2021 Jul 2. PubMed 34604341 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Nov 2021, 61 months.

Results were first posted in Jan 2023, 1 year 1 month after primary completion. A results delay was requested in Nov 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2016
First posted
Nov 16, 2016
StartActual
Sep 23, 2016
Primary completionActual
Nov 17, 2021
CompletionActual
Nov 17, 2021
Results delay requested
Nov 4, 2020
Results first posted
Jan 3, 2023
Last update
Jan 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02964273
Responsible party
Sponsor
First posted
Nov 16, 2016
Start date
Sep 23, 2016
Primary completion
Nov 17, 2021
Completion
Nov 17, 2021
Results posted
Jan 3, 2023
Last update
Jan 3, 2023

Study contacts

Study Director
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion